InMed Pharmaceuticals (InMed Pharmaceuticals) Growth Rank : 0 (As of Jun. 09, 2024)

View and export this data going back to . Start your Free Trial

What is InMed Pharmaceuticals Growth Rank?

InMed Pharmaceuticals has the Growth Rank of 0.

GuruFocus Growth Rank measures the growth of a company in terms of its revenue and profitability. Historically, the companies with the highest growth ranks performed the best over the long term. It is calculated using the following criteria:

1. 5-year revenue growth rate, the higher, the better.
2. 3-year revenue growth rate, the higher, the better.
3. 5-year EBITDA growth rate, the higher, the better.
4. The predictability of 5-year revenue. The most consistent it is, the higher the rank.

GuruFocus found that the Growth Rank is the second of the two most-sensitive parameters among the five parameters checked. Please click GF Score to see more details on GF Score's 5 Key Aspects of Analysis.

Please note that we are using the five-year EBITDA growth rate as a parameter, so the company needs to have had positive growth over that time. The reason we use EBITDA instead of earnings per share is that with EBITDA, we can rank a lot more companies since a company may have positive EBITDA but negative EPS. Since we are looking at the growth here, EBITDA gives us a pretty clear picture about the growth in the company's business operations.

InMed Pharmaceuticals Growth Rank Related Terms

Thank you for viewing the detailed overview of InMed Pharmaceuticals's Growth Rank provided by GuruFocus.com. Please click on the following links to see related term pages.

InMed Pharmaceuticals (InMed Pharmaceuticals) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » InMed Pharmaceuticals Inc (NAS:INM) » Definitions » Growth Rank

Comparable Companies

Traded in Other Exchanges

MWG0:Germany

Address

815 West Hastings Street, Suite 310, Vancouver, BC, CAN, V6C 1B4

Website

https://www.inmedpharma.com

InMed Pharmaceuticals Inc is a Canada based clinical-stage biopharmaceutical company. The company is engaged in the research and development of novel, cannabinoid-based, and manufacturing of Pharmaceutical grade cannabinoids. Its product portfolio includes INM-755, which is used for the treatment of epidermolysis bullosa; INM-088 for the treatment of glaucoma; and IntegraSyn which is a manufacturing system for Pharmaceutical-Grade Cannabinoids.

Executives

Jonathan Tegge	officer: Interim CFO	217 W. MAIN STREET, SOMERVILLE NJ 08876
Sarah Li	officer: VP, Accounting and Controller	310-815 WEST HASTINGS ST., VANCOUVER Z4 V6C1B4
Nicole Lemerond	director	3 MURRAY HILL ROAD, SCARSDALE NY 10583
Bryan T Baldasare	director	3471 RIVER HILLS DRIVE, CINCINNATI OH 45244
Eric A Adams	director, officer: President & CEO	C/O INMED PHARMACEUTICALS INC., SUITE 310 - 815 HASTINGS STREET, VANCOUVER A1 V6C 1B4
Brenda Edwards	officer: Interim CFO	111-1232 JOHNSON ST., COQUITLAM A1 V3B 4T2
Janet P Grove	director	510 WEST GEORGIA STREET, SUITE 1800, VANCOUVER A1 V5T 4T5
Bruce Colwill	officer: CFO	C/O INMED PHARMACEUTICALS INC., SUITE 310 - 815 HASTINGS STREET, VANCOUVER A1 V6C 1B4
Shane Aaron Johnson	officer: SVP & GM of BayMedica LLC	930 TAHOE BLVD., SUITE 802-433, INCLINE VILLAGE NV 89451
Adam D. Cutler	director	9301 AMBERGLEN BOULEVARD, SUITE 100, C/O MOLECULAR TEMPLATES, INC., AUSTIN TX 78729
William J Garner	director	875 MAHLER ROAD, SUITE 235, BURLINGAME CA 94010
Catherine Sazdanoff	director	3471 RIVER HILLS DRIVE, CINCINNATI OH 45244
Eric C Hsu	officer: Sr. VP, Pre-Clinical Res/Dev	C/O INMED PHARMACEUTICALS INC., SUITE 310 - 815 HASTINGS STREET, VANCOUVER A1 V6C 1B4
Michael Woudenberg	officer: VP, Chem/Manufacturing/Control	C/O INMED PHARMACEUTICALS INC., SUITE 310 - 815 HASTINGS STREET, VANCOUVER A1 V6C 1B4
Mancini Alexandra Diane Janet	officer: Sr VP, Clinical Reg Affairs	C/O INMED PHARMACEUTICALS INC., SUITE 310 - 815 HASTINGS STREET, VANCOUVER A1 V6C 1B4